(Reuters) -Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.
On an adjusted basis, the company earned $11.59 per share for the quarter, above analysts’ estimates of $10.72, according to LSEG data.
Anti-inflammatory drug Dupixent, which was approved in 2017, has aided Regeneron’s profits while sales of its eye drug Eylea has taken a backseat in recent quarters owing to increased competition from Roche’s Vabysmo.
Quarterly sales of Dupixent, recorded by its partner Sanofi, rose 33% to $3.10 billion.
Eylea sales for the quarter was $1.49 billion, which included $43 million sales from the higher dose, or 8 milligram dose that recently received approval in the United States.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta and Maju Samuel)
